Rina-S

Phase 3Small molecule

Genmab

Rina-S is one of 129 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Endometrial CancerActive, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Recruiting

Gastrointestinal CancersRecruiting

Epithelial Ovarian CancerRecruiting

Platinum-Resistant Ovarian CancerActive, not recruiting

Platinum Sensitive Ovarian CancerNot yet recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Endometrial CancerPhase 3

Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Phase 2

Recruiting

Gastrointestinal CancersPhase 2

Recruiting

Epithelial Ovarian CancerPreclinical

Recruiting

Platinum-Resistant Ovarian CancerPhase 3

Active, not recruiting

Platinum Sensitive Ovarian CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Rina-S

Genmab

Phase 3

8 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Lenvima

Eisai

Preclinical

6 4

Vizimpro

Pfizer

Preclinical

4 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

3 9

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

3 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Epithelial Ovarian Cancer

NCT05579366

Q2 2028

Phase 3Active, not recruiting

Platinum-Resistant Ovarian Cancer

NCT06619236

Q4 2028

Phase 2Recruiting

Gastrointestinal Cancers

NCT07539311

Phase 2Recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT07288177

Phase 3Not yet recruiting

Platinum-Resistant Ovarian Cancer

NCT07604766

Q4 2029

Phase 3Recruiting

Endometrial Cancer

NCT07166094

Clinical

Trials by Indication[1]

Platinum-resistant Ovarian Cancer2 trials

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

Not yet recruiting· Genmab logo

Genmab·Phase 3·NCT07604766·82 enrolled

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

Active, not recruiting· Genmab logo

Genmab·Phase 3·NCT06619236·530 enrolled

Ovarian Cancer1 trial

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Recruiting· Genmab logo

Genmab·Phase 3·NCT07225270·528 enrolled

Epithelial Ovarian Cancer1 trial

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Recruiting· Genmab logo

Genmab·Preclinical·NCT05579366·884 enrolled

Gastrointestinal Cancers1 trial

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

Recruiting· Genmab logo

Genmab·Phase 2·NCT07539311·160 enrolled

Endometrial Cancer1 trial

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Recruiting· Genmab logo

Genmab·Phase 3·NCT07166094·660 enrolled

2 more indications

Platinum Sensitive Ovarian Cancer1 trial

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Not yet recruiting· Genmab logo

Genmab·Phase 3·NCT07564141·688 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer

Recruiting· Genmab logo

Genmab·Phase 2·NCT07288177·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Rina-S. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rina-S compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rina-S. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Genmab

Rina-S

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q4 2028

Q4 2029

Trials by Indication[1]

Platinum-resistant Ovarian Cancer2 trials

Ovarian Cancer1 trial

Epithelial Ovarian Cancer1 trial

Gastrointestinal Cancers1 trial

Endometrial Cancer1 trial

Platinum Sensitive Ovarian Cancer1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News